Vysotskaia, V., Kaseniit, K. E., Bucheit, L., Ready, K., Price, K., & Johansen Taber, K. (2019). Clinical utility of hereditary cancer panel testing: Impact of PALB2, ATM, CHEK2, NBN, BRIP1, RAD51C, and RAD51D results on patient management and adherence to provider recommendations. Cancer.
Citação norma ChicagoVysotskaia, Valentina, K. Eerik Kaseniit, Leslie Bucheit, Kaylene Ready, Kristin Price, and Katherine Johansen Taber. "Clinical Utility of Hereditary Cancer Panel Testing: Impact of PALB2, ATM, CHEK2, NBN, BRIP1, RAD51C, and RAD51D Results On Patient Management and Adherence to Provider Recommendations." Cancer 2019.
Citação norma MLAVysotskaia, Valentina, et al. "Clinical Utility of Hereditary Cancer Panel Testing: Impact of PALB2, ATM, CHEK2, NBN, BRIP1, RAD51C, and RAD51D Results On Patient Management and Adherence to Provider Recommendations." Cancer 2019.